TY - JOUR
T1 - A new aspect of an old friend
T2 - The beneficial effect of metformin on anti-tumor immunity
AU - Kim, Kyeong Jin
AU - Yang, Wen Hao
AU - Jung, Youn Sang
AU - Cha, Jong Ho
N1 - Funding Information:
This work was supported in part by the following: The National Research Foundation of Korea (NRF) grant funded by the Korea government Ministry of Science and ICT (MSIT) (2020R1C1C1 005631 to J.-H. Cha and 2020R1C1C1004015 to K. Kim), INHA UNIVERSITY Research Grant [to K. Kim and J.-H. Cha], Ying Tsai Young Scholar Award (CMU108-YTY-04), the Ministry of Science and Technology (MOST; 109-2314-B-039-054) [to W.-H. Yang], and CHUNG-ANG UNIVERSITY Grant [to Y.-S. Jung].
Publisher Copyright:
© 2020 by the The Korean Society for Biochemistry and Molecular Biology
PY - 2020
Y1 - 2020
N2 - T-cell-based cancer immunotherapies, such as immune checkpoint blockers (ICBs) and chimeric antigen receptor (CAR)-Tcells, have significant anti-tumor effects against certain types of cancer, providing a new paradigm for cancer treatment. However, the activity of tumor infiltrating T-cells (TILs) can be effectively neutralized in the tumor microenvironment (TME) of most solid tumors, rich in various immunosuppressive factors and cells. Therefore, to improve the clinical outcomes of established T-cell-based immunotherapy, adjuvants that can comprehensively relieve multiple immunosuppressive mechanisms of TME are needed. In this regard, recent studies have revealed that metformin has several beneficial effects on anti-tumor immunity. In this mini-review, we understand the immunosuppressive properties of TME and how metformin comprehensively enhances anti-tumor immunity. Finally, we will discuss this old friend’s potential as an adjuvant for cancer immunotherapy.
AB - T-cell-based cancer immunotherapies, such as immune checkpoint blockers (ICBs) and chimeric antigen receptor (CAR)-Tcells, have significant anti-tumor effects against certain types of cancer, providing a new paradigm for cancer treatment. However, the activity of tumor infiltrating T-cells (TILs) can be effectively neutralized in the tumor microenvironment (TME) of most solid tumors, rich in various immunosuppressive factors and cells. Therefore, to improve the clinical outcomes of established T-cell-based immunotherapy, adjuvants that can comprehensively relieve multiple immunosuppressive mechanisms of TME are needed. In this regard, recent studies have revealed that metformin has several beneficial effects on anti-tumor immunity. In this mini-review, we understand the immunosuppressive properties of TME and how metformin comprehensively enhances anti-tumor immunity. Finally, we will discuss this old friend’s potential as an adjuvant for cancer immunotherapy.
KW - Adjuvant
KW - Cancer immunotherapy
KW - Cold tumor and tumor icroenvironment
KW - Metformin
UR - http://www.scopus.com/inward/record.url?scp=85094933428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094933428&partnerID=8YFLogxK
U2 - 10.5483/BMBRep.2020.53.10.149
DO - 10.5483/BMBRep.2020.53.10.149
M3 - Article
C2 - 32731915
AN - SCOPUS:85094933428
SN - 1976-6696
VL - 53
SP - 512
EP - 520
JO - BMB Reports
JF - BMB Reports
IS - 10
ER -